Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Milestone Pharmaceuticals Inc. (MIST)

5.1555   0.156 (3.11%) 11-28 10:50
Open: 5 Pre. Close: 5
High: 5.2 Low: 5
Volume: 64,155 Market Cap: 177(M)

Technical analysis

as of: 2022-11-28 10:20:21 AM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 6.85     One year: 8
Support: Support1: 4.73    Support2: 4.03
Resistance: Resistance1: 5.86    Resistance2: 6.85
Pivot: 4.6
Moving Average: MA(5): 4.94     MA(20): 4.7
MA(100): 6.97     MA(250): 6.51
MACD: MACD(12,26): -0.4     Signal(9): -0.6
Stochastic oscillator: %K(14,3): 89.5     %D(3): 79.8
RSI: RSI(14): 48.3
52-week: High: 9.84  Low: 3.98
Average Vol(K): 3-Month: 732 (K)  10-Days: 274 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ MIST ] has closed below upper band by 3.8%. Bollinger Bands are 43.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 5.03 - 5.06 5.06 - 5.08
Low: 4.87 - 4.9 4.9 - 4.92
Close: 4.95 - 5 5 - 5.04

Company Description

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Headline News

Mon, 28 Nov 2022
Mist Pre-Alpha Phase 2 Announced for November 30 Launch By DailyCoin -

Sun, 27 Nov 2022
Find the Best Body Mist for Men only on Amazon - Economic Times

Fri, 25 Nov 2022
'The Mist' at 15: Greg Nicotero compares Stephen King adaptation to John Carpenter's 'The Thing' - Syfy

Fri, 25 Nov 2022
Margot Robbie's go-to face mist is 25% off this Black Friday 2022 - Cosmopolitan UK

Wed, 23 Nov 2022
Ocean Mist® Farms Details Peak Fall Brussels Sprouts Crop; Mark Munger Comments - And Now U Know

Sat, 19 Nov 2022
Autumn Mist Farm celebrates three months of business - Western Massachusetts News

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 34 (M)
% Held by Insiders 2.048e+007 (%)
% Held by Institutions 1.1 (%)
Shares Short 845 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -6.27e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -4
Return on Assets (ttm) 186.7
Return on Equity (ttm) -35.8
Qtrly Rev. Growth 1.5e+006
Gross Profit (p.s.) 0
Sales Per Share -29.62
EBITDA (p.s.) 7.31707e+006
Qtrly Earnings Growth -1.1
Operating Cash Flow 0 (M)
Levered Free Cash Flow -52 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.18
Price to Cash Flow 4.15

Stock Dividends

Dividend 0
Forward Dividend 878260
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.